This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ibopamine is a sympathomimetic, indicated in the induction of mydriasis and treatment of pos-surgical ocular hypotonia.
- Generic Name
- Ibopamine
- DrugBank Accession Number
- DB13316
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Ibopamine (DB13316)
- Weight
- Average: 307.3847
Monoisotopic: 307.178358293 - Chemical Formula
- C17H25NO4
- Synonyms
- Ibopamine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareEmpagliflozin Empagliflozin may increase the diuretic activities of Ibopamine. Insulin aspart The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Ibopamine. Insulin beef The therapeutic efficacy of Insulin beef can be decreased when used in combination with Ibopamine. Insulin degludec The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Ibopamine. Insulin detemir The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Ibopamine. Insulin glargine The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Ibopamine. Insulin glulisine The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Ibopamine. Insulin human The therapeutic efficacy of Insulin human can be decreased when used in combination with Ibopamine. Insulin lispro The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Ibopamine. Insulin pork The therapeutic efficacy of Insulin pork can be decreased when used in combination with Ibopamine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- S01FB03 — Ibopamine
- S01FB — Sympathomimetics excl. antiglaucoma preparations
- S01F — MYDRIATICS AND CYCLOPLEGICS
- S01 — OPHTHALMOLOGICALS
- S — SENSORY ORGANS
- Drug Categories
- Adrenergic and Dopaminergic Agents
- Agents that produce hypertension
- Amines
- Autonomic Agents
- Benzene Derivatives
- Cardiac Stimulants Excl. Cardiac Glycosides
- Cardiac Therapy
- Cardiotonic Agents
- Cardiovascular Agents
- Catecholamines
- Catechols
- Compounds used in a research, industrial, or household setting
- Diuretics
- Dopamine Agents
- Dopamine Agonists
- Dopamine D1 Receptor Agonists
- Epinephrine and similars
- Mydriatics
- Mydriatics and Cycloplegics
- Natriuretic Agents
- Neurotransmitter Agents
- Ophthalmologicals
- Peripheral Nervous System Agents
- Phenols
- Protective Agents
- Sensory Organs
- Sympathomimetics Excl. Antiglaucoma Preparations
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenol esters. These are aromatic compounds containing a benzene ring substituted by a hydroxyl group and an ester group.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Phenol esters
- Sub Class
- Not Available
- Direct Parent
- Phenol esters
- Alternative Parents
- Phenethylamines / Phenoxy compounds / Aralkylamines / Dicarboxylic acids and derivatives / Carboxylic acid esters / Amino acids and derivatives / Dialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives show 1 more
- Substituents
- Amine / Amino acid or derivatives / Aralkylamine / Aromatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dicarboxylic acid or derivatives / Hydrocarbon derivative / Monocyclic benzene moiety show 11 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 8ZCA2I2L11
- CAS number
- 66195-31-1
- InChI Key
- WDKXLLJDNUBYCY-UHFFFAOYSA-N
- InChI
- InChI=1S/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3
- IUPAC Name
- 5-[2-(methylamino)ethyl]-2-[(2-methylpropanoyl)oxy]phenyl 2-methylpropanoate
- SMILES
- CNCCC1=CC(OC(=O)C(C)C)=C(OC(=O)C(C)C)C=C1
References
- General References
- AIFA Package Leaflet: TRAZYL (Ibopamine) ophthalmic solution [Link]
- External Links
- Human Metabolome Database
- HMDB0041906
- ChemSpider
- 61829
- 51253
- ChEBI
- 135306
- ChEMBL
- CHEMBL307739
- ZINC
- ZINC000001542906
- Wikipedia
- Ibopamine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Solution / drops Ophthalmic - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.05 mg/mL ALOGPS logP 3.33 ALOGPS logP 3.52 Chemaxon logS -3.8 ALOGPS pKa (Strongest Basic) 10.01 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 64.63 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 84.73 m3·mol-1 Chemaxon Polarizability 34.36 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at June 23, 2017 20:39 / Updated at June 02, 2021 20:04